Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

825 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma.
Yoshikawa T, Tsuburaya A, Hirabayashi N, Yoshida K, Nagata N, Kodera Y, Takahashi N, Oba K, Kimura M, Ishikura S, Miyashita Y, Sakamoto J. Yoshikawa T, et al. Among authors: miyashita y. Cancer Chemother Pharmacol. 2009 Nov;64(6):1071-7. doi: 10.1007/s00280-009-0963-3. Epub 2009 Mar 13. Cancer Chemother Pharmacol. 2009. PMID: 19283353 Clinical Trial.
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J; Japanese South West Oncology Group (JASWOG). Ninomiya M, et al. Among authors: miyashita y. J Chemother. 2007 Aug;19(4):444-50. doi: 10.1179/joc.2007.19.4.444. J Chemother. 2007. PMID: 17855190 Clinical Trial.
A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, Miyashita Y, Sakamoto J. Yoshikawa T, et al. Among authors: miyashita y. Jpn J Clin Oncol. 2010 Apr;40(4):369-72. doi: 10.1093/jjco/hyp178. Epub 2010 Mar 18. Jpn J Clin Oncol. 2010. PMID: 20299499 Clinical Trial.
Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study.
Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hasegawa S, Aoyama T, Hayashi T, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Yoshikawa T, et al. Among authors: miyashita y. Ann Surg Oncol. 2014 Jun;21 Suppl 3:S385-9. doi: 10.1245/s10434-014-3615-8. Epub 2014 Mar 5. Ann Surg Oncol. 2014. PMID: 24595801 Clinical Trial.
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: miyashita y. Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18. Eur J Cancer. 2015. PMID: 25797356 Free article. Clinical Trial.
Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, Hayashi T, Cho H, Tsuburaya A, Miyashita Y, Sakamoto J. Yoshikawa T, et al. Among authors: miyashita y. Eur J Cancer. 2016 Jul;62:103-11. doi: 10.1016/j.ejca.2016.04.012. Epub 2016 May 28. Eur J Cancer. 2016. PMID: 27244537 Free article. Clinical Trial.
A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K, Tsuburaya A, Yoshikawa T, Takahashi M, Tanabe K, Yamaguchi K, Yoshino S, Namikawa T, Aoyama T, Rino Y, Kawada J, Tsuji A, Taira K, Kimura Y, Kodera Y, Hirashima Y, Yabusaki H, Hirabayashi N, Fujitani K, Miyashita Y, Morita S, Sakamoto J. Nishikawa K, et al. Among authors: miyashita y. Gastric Cancer. 2018 Sep;21(5):811-818. doi: 10.1007/s10120-018-0815-0. Epub 2018 Feb 27. Gastric Cancer. 2018. PMID: 29488122 Clinical Trial.
825 results